Taught a model the physics, not just the data
At Amgen, hybrid mechanistic and machine learning models cut the experiments needed for process characterization by more than half, without giving up accuracy.
John Zeeman
Chemical engineer by training, strategist by habit. MIT Leaders for Global Operations (MBA and SM in Chemical Engineering), after four years in Deloitte's Cell and Gene Therapy practice and a stretch building machine learning tools at Amgen.
At Amgen, hybrid mechanistic and machine learning models cut the experiments needed for process characterization by more than half, without giving up accuracy.
Four years in Deloitte's Cell and Gene Therapy practice, building commercial launch plans and operating models for companies turning science into scale.
MIT Leaders for Global Operations paired an MBA with a Master's in Chemical Engineering, built for leading in industries where the engineering is the business.
Currently exploring
Featured writing
All writing →Based in the Chicago area through the summer, moving to Cambridge, MA in August 2026. Always happy to talk biotech, operations, and company-building. Open to what's next.